U.S. Markets closed

3SBio Inc. (1530.HK)

HKSE - HKSE Delayed Price. Currency in HKD
Add to watchlist
5.890-0.320 (-5.15%)
At close: 04:08PM HKT

3SBio Inc.

No. 3 A1, Road 10
Shenyang Economy and Technology Developm
Shenyang 110027
86 24 2538 6000

Full Time Employees5,232

Key Executives

NameTitlePayExercisedYear Born
Dr. Jing LouCo-Founder, Exec. Chairman, CEO & Pres586.86kN/A1963
Dr. Dongmei SuSr. VP & Exec. Director219.44kN/A1970
Mr. Fei WangChief Financial OfficerN/AN/A1978
Mr. Weihong XiaoChief Operating OfficerN/AN/A1969
Ms. Lu XiaDirector of Investor RelationsN/AN/A1985
Ms. Hui DangDirector of Risk and Compliance ManagementN/AN/A1972
Mr. Thomas Folinsbee C.F.A., CFADirector of Corp. Devel.N/AN/A1968
Mr. Xin MaVP of the HR DepartmentN/AN/A1961
Ms. Fei YouDirector of the Fin. Department & Financial ControllerN/AN/A1979
Mr. Junlin WangPres of GuojianN/AN/A1973
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.


3SBio Inc. researches, develops, manufactures, markets, and sells biopharmaceutical products in the People's Republic of China. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; YISAIPU, a tumor necrosis factor for rheumatoid arthritis, ankylosing spondylitis, and psoriasis; EPIAO and SEPO recombinant human erythropoietins to treat anemia; and Cipterbin for HER2-positive metastatic breast cancer in combination with chemotherapy. It also offers Mandi to treat male alopecia and alopecia areata; Xenopax for preventing acute rejection after renal transplant; Byetta for the glycemic control in patients with type 2 diabetes; Qiming Keli to treat retinopathy caused by type 2 diabetic; Aiyishu for iron-deficiency anemia; and SPARIN, an injectable low-molecular-weight heparin calcium for the treatment of prophylaxis and deep vein thrombosis, as well as for the prevention of clotting during hemodialysis. In addition, it offers Intefen, a recombinant human interferon to treat lymphatic or hematopoietic malignancies and viral infections; and Inleusin, a human interleukin2 for the treatment of renal cell carcinoma, melanoma, and thoracic fluid build-up. Further, the company provides trading, project management and consultation, technology, and agricultural services. It has collaboration agreements with companies, such as AstraZeneca, Lilly, Toray, Samsung Bioepis, Refuge Biotechnologies, Verseau, TLC, Numab, GenSight, Sensorion, and INV. The company was founded in 1993 and is headquartered in Shenyang, the People's Republic of China.

Corporate Governance

3SBio Inc.’s ISS Governance QualityScore as of September 26, 2021 is 6. The pillar scores are Audit: 7; Board: 6; Shareholder Rights: 2; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.